Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [41] Health-related quality of life after curative treatment for muscle-invasive bladder cancer
    Elisabeth Grobet-Jeandin
    Ugo Pinar
    Jérôme Parra
    Morgan Rouprêt
    Thomas Seisen
    Nature Reviews Urology, 2023, 20 : 279 - 293
  • [42] Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment
    Schulz, G. B.
    Stief, C. G.
    Schlenker, B.
    UROLOGE, 2019, 58 (09): : 1093 - 1106
  • [43] Efficacy of curative radiotherapy for the treatment of elderly patients with muscle-invasive bladder cancer: a systematic review
    Sakaguchi, Masakuni
    Maebayashi, Toshiya
    Sekino, Yuta
    Ishikawa, Hitoshi
    BMC UROLOGY, 2025, 25 (01):
  • [44] Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer
    Goossens-Laan, Catharina A.
    Leliveld, Anna M.
    Verhoeven, Rob H. A.
    Kil, Paul J. M.
    de Bock, Geertruida H.
    Hulshof, Maarten C. C. M.
    de Jong, Igle J.
    Coebergh, Jan Willem W.
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (04) : 905 - 912
  • [45] Re: EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
    de Jong, Joep J.
    Lotan, Yair
    Boormans, Joost L.
    EUROPEAN UROLOGY, 2024, 86 (05) : 480 - 481
  • [46] Muscle-invasive bladder cancer
    Kuebler, H.
    Gschwend, J. E.
    ONKOLOGE, 2012, 18 (11): : 977 - +
  • [47] Muscle-Invasive Bladder Cancer
    Hasan, Shaakir
    Chhabra, Arpit M.
    Choi, J. Isabelle
    Simone, Charles B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : 309 - 310
  • [48] Muscle-invasive bladder cancer
    Buchler, Jakob
    Gschwend, Juergen E.
    Retz, Margitta
    Schmid, Sebastian C.
    UROLOGE, 2021, 60 (06): : 769 - 775
  • [49] Role of PET/CT in muscle-invasive bladder cancer
    Kim, Seok-ki
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) : 2908 - 2919
  • [50] Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
    Youssef, Ramy F.
    Lotan, Yair
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 369 - 381